Labiotech.eu

How are biotechs tackling this rare lung disease? 🫁 Idiopathic pulmonary fibrosis (IPF) is a condition where the lungs become scarred, making it hard for people to breathe. 😮💨 There are a lot of drugs being tested in the clinic. Some of these include candidates owned by Boehringer Ingelheim, Insilico Medicine, Endeavor BioMedicines, Vicore Pharma AB, Bristol Myers Squibb, and Pliant Therapeutics, among others. 🏥 💰 Just this morning Refoxy Pharma announced a €9.1 million funding round to advance its preclinical IPF drug. Labiotech spoke to Refoxy’s co-founder Victor Bustos about the candidate.  Read our latest article to learn more about the therapeutic space! 👇 https://lnkd.in/dPzjuYbz #idiopathicpulmonaryfibrosis #rarelungdisease #pulmonaryhealth #biotechinnovation #biotechfunding #innovativetherapies #respiratoryresearch #medicalbreakthroughs Surrozen | Arda Therapeutics | Contineum Therapeutics | Pulmonary Fibrosis Foundation | British Lung Foundation | Canadian Pulmonary Fibrosis Foundation | Lung Foundation Australia | American Thoracic Society | National Heart, Lung, and Blood Institute | Coalition for Pulmonary Fibrosis

3D organoids: The key to reducing drug development costs? 💸 With drug development costs soaring, 3D organoids are emerging as a powerful tool to improve preclinical research accuracy. By better mimicking human physiology, organoids can help increase the success rate of drug candidates, saving time and money. ⏱️ Dive into our latest Sartorius-sponsored report to see how 3D organoids are transforming drug development. 🗒️ Full report available here ⬇️ https://lnkd.in/d-sqffs9 #3Dorganoids #biomedicalresearch #drugdiscovery #healthcareinnovation #organoidtechnology #biotechrevolution #biotechtrends

Socks and sweaters are great gifts for the winter, but sometimes, a bit of biotech love goes a long way. 💕🧬 Labiotech has created a list of biotechnology-themed holiday gifts to get for your friends and family. 🎁 🍄 From glow-in-the-dark mushrooms and DIY biology kits to portable DNA sequencers and DNA-shaped utensils to bake goodies, you have this holiday sorted. 🍪 🎅 Read our latest article if you’re looking for great gift ideas to get your loved ones who are big biotech buffs this holiday season! 👇 https://lnkd.in/dXNi6HRt #biotechgifts #holidayshopping #techiegifts #innovativepresents #biotechfun #holidayideas 

How is biopharma accelerating innovation? 🚀 Process intensification is becoming a vital tool for modern biopharma, and KBI Biopharma is at the forefront of implementing these advanced strategies. By combining continuous processing, single-use systems, and automation, KBI supports more efficient workflows while ensuring high product quality. 💡 A recent example includes their work on a molecule where a shift to perfusion processes reduced fragmentation by 90%, significantly improving stability. ✅ Full article below! ⬇️ https://lnkd.in/dtwpHvdR   #biopharmainnovation #processintensification #biopharmaresearch #molecularstability #healthcareinnovation #biotechadvances

Can cancer vaccines reshape oncology? 🛡️ Cancer vaccines are emerging as a transformative force in immunotherapy, harnessing the immune system to combat cancer. These vaccines fall into two categories: preventive, aimed at averting cancers like HPV-related types, and therapeutic, designed to stimulate immune responses against existing tumors. 💉 With advances in mRNA, DNA, peptide-based, and cell-based technologies, cancer vaccines are targeting a diverse range of tumors. From personalized neoantigen mRNA vaccines to viral vector approaches like oncolytic viruses, the field is innovating rapidly. Promising clinical data, combined with the success of immuno-oncology, has driven the cancer vaccine market to a projected $42.58 billion by 2032, growing at a CAGR of 17%. 🔬 Could this be the dawn of a new era in cancer treatment? 👇️ https://lnkd.in/du6qJRP2 #cancervaccines #oncologybreakthroughs #immunotherapy #mRNAtechnology #preventivemedicine #biotechinnovation #cancerresearch #immunooncology  Moderna | Merck | BioNTech SE | Nykode Therapeutics | Genentech | INOVIO Pharmaceuticals, Inc. | Immatics | MimiVax, Inc. | Amgen | Dendreon

Weekly Recap of the Hottest M&A and Partnerships in the Biotech World! 🔥🤝 Merger and acquisition: 🔀                                                                                🇨🇭 Roche acquires 🇺🇸 Poseida Therapeutics, Inc. | total equity value of up to $1.5 billion | Lead asset: CAR-T candidate for multiple myeloma 🇨🇭 Novartis acquires 🇺🇸 Kate Therapeutics | Kate to receive up to $1.1 billion in upfront and milestone payments | Lead asset: gene therapy for X-linked myotubular myopathy Partnering: 🤝 🇺🇸 Arrowhead Pharmaceuticals collaborates with 🇺🇸 Sarepta Therapeutics | Arrowhead to receive $825 million in an upfront payment and equity investment, an additional $250 million, and up to $300 million in near-term milestone payments, and up to $10 billion in future milestone payments 🇺🇸 23andMe and 🇺🇸 Mirador Therapeutics collaborate to develop precision medicines for immunology and inflammation | undisclosed financial terms  Subscribe to our newsletter for more partnering updates!  🔗 https://lnkd.in/dsgz62YY #deals #partnering #mergers #acquisitions #biotech

What do Trump’s picks for the top healthcare roles in the U.S. mean for the country? 🏥 In the new year, Donald Trump will take over the highest office in the U.S. 🇺🇸 His healthcare nominees have big plans and they are not short of controversy. 💉❌ 💼 If approved by the Senate, anti-vaccine activist Robert F Kennedy Jr would be tasked with leading the U.S. Health department. Trump has also set his sights on who will run the FDA, NIH, and the CDC. Read our latest article to find out about what this could mean for U.S. healthcare. 👇 https://lnkd.in/d6Nng6dq #UShealthcare #healthcarepolicy #healthleadership #publichealth #healthcarefuture #biotechnews

Can biotech beat mosquito-borne diseases? 🦟 With mosquito-borne diseases on the rise, British biotech Oxitec recently launched Sparks, a platform targeting dengue fever. 🌡️ Backed by Bill & Melinda Gates Foundation’s multi-million-dollar investment, Sparks adds to Oxitec’s Aedes aegypti technology called Friendly, which is taking on dengue fever in Brazil. 🤒 These Friendly mosquitoes are designed to suppress populations of disease-spreading mosquitoes and, in turn, reduce biting and the threat of disease transmission. 📉 🎧 On Labiotech’s Beyond Biotech Podcast episode today, we have Oxitec’s CEO Grey Frandsen. Tune into the latest episode to learn more about this company’s mission to tackle the viral infection. 👇 https://lnkd.in/dZFyN8kh #BeyondBiotechPodcast #infectiousdiseases #denguefever #biotechsolutions #diseaseprevention #globalhealth 

💰 Biotech's Top Investments This Week! 🚀 🇺🇸 Replimune | $140 million public offering | cancer immunotherapies | phase 3 in melanoma 🇩🇰 Adcendo | $135 million series B | antibody-drug conjugates | phase 1/2 in soft tissue sarcoma 🇺🇸 Enveda | $130 million series C | drug discovery | phase 1 in atopic dermatitis 🇺🇸 Cidara Therapeutics | $105 million private placement | immunotherapies | phase 2 in seasonal influenza 🇳🇱 Cradle | $73 million series B | AI-powered protein engineering 🇨🇦 35Pharma | $53 million series C | activin inhibitors | phase 1 in pulmonary hypertension, cardiometabolic disease and obesity 🇺🇸 Valora Therapeutics, Inc. | $30 million seed | immunotherapies 🇺🇸 Aizen Therapeutics | $13 million financing | mirror peptides 🇨🇦 Aptose Biosciences, Inc. | $8 million public offering | cancer medicines | phase 2/3 in myeloid tumors 🇺🇸 BioXcel Therapeutics, Inc. | $7 million public offering | neuroscience | phase 3 in schizophrenia  🇮🇱 Converge Bio | $5.5 million seed | AI-enabled drug discovery and development   Subscribe to our newsletter for more fundraising updates! 🔗 https://lnkd.in/dsgz62YY #fundraising #funding #biotech #venturecapital #fundinground #biotechstartup #seriesa #seriesb #seriesc #investors #IPO #seedfunding

Antisense oligonucleotides are gaining popularity among drug developers, as they are a highly specific, targeted treatment that can treat a wide range of diseases. 🧬 These drugs are essentially short, single-stranded synthetic fragments of DNA or RNA that bind specifically to the target RNA sequence inside cells and modulate protein expression through several mechanisms. 💊 With more companies slowly entering the antisense oligonucleotide field, the global market for these drugs is expected to amass a revenue of around $5,519 million by 2033. 🌍 📈 Read our latest article to learn about six antisense oligonucleotide companies leading the way! 👇️ https://lnkd.in/d4ysAjCA   #antisenseoligonucleotides #targetedtherapies #RNAinnovation #drugdevelopment #biotechbreakthroughs #molecularmedicine #biotechindustry Ionis Pharmaceuticals, Inc. | Isarna Therapeutics GmbH | Regulus Therapeutics | Sarepta Therapeutics | Secarna Pharmaceuticals | Wave Life Sciences